Government supplementary budget for COVID-19 medical and pharma measures Japan 2020
coronavirus disease (COVID-19) on April 20, 2020. A total expense of around 1.8 trillion Japanese yen was planned for medical and pharmaceutical related measures, 13.9 billion yen of which were for securing the antiviral drug Avigan (Favipiravir). Only 10 billion yen were for supporting the development of vaccines in the country, while close to 22 billion yen were prepared for supporting the development of vaccines internationally.
For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated facts and figures page.
The Japanese government announced the supplementary budged related to the economic stimulus package concerning For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated facts and figures page.